Literature DB >> 2110117

Correlation of hepatitis C virus antibodies with HIV-1 seropositivity in intravenous drug addicts.

H P Huemer, W M Prodinger, C Larcher, L Möst, M P Dierich.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2110117     DOI： 10.1007/bf01641432

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  11 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Antibodies to hepatitis C virus in French blood donors.

Authors:  C Janot; A M Couroucé; M Maniez
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  Discovery of the non-A, non-B hepatitis virus: the end of the beginning or the beginning of the end.

Authors:  H J Alter
Journal:  Transfus Med Rev       Date:  1989-04

5.  Antibody to hepatitis C virus in German blood donors.

Authors:  P Kühnl; S Seidl; W Stangel; J Beyer; W Sibrowski; J Flik
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

6.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

7.  Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.

Authors:  M Colombo; G Kuo; Q L Choo; M F Donato; E Del Ninno; M A Tommasini; N Dioguardi; M Houghton
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

8.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

9.  Fulminant NANB hepatitis in a patient with AIDS: a possible demonstration of direct hepatic damage by the virus/es involved?

Authors:  M Libanore; R Bicocchi; L Sighinolfi; F Ghinelli
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728
View more
  7 in total

1.  Sexual transmission of hepatitis C virus and HIV-1 infection in female intravenous drug users.

Authors:  A Salvaggio; M Conti; A Albano; A Pianetti; M L Muggiasca; M Re; L Salvaggio
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

2.  Antibody to hepatitis C virus in risk groups in Canada.

Authors:  R Chaudhary; T Mo
Journal:  Can J Infect Dis       Date:  1992-01

3.  Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection.

Authors:  A Sönnerborg; A Abebe; O Strannegård
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

4.  Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain.

Authors:  O E Santana Rodríguez; M L Malé Gil; J F HernándezSantana; J M Limiñana Cañal; A M Martín Sánchez
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

5.  HCV, HIV, HBV and HDV infections in intravenous drug addicts.

Authors:  R C Coppola; P E Manconi; R Piro; M L Di Martino; G Masia
Journal:  Eur J Epidemiol       Date:  1994-06       Impact factor: 8.082

6.  Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients.

Authors:  D Francisci; F Baldelli; R Papili; G Stagni; S Pauluzzi
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

7.  Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.

Authors:  Wei Zhang; Michael A Nardi; William Borkowsky; Zongdong Li; Simon Karpatkin
Journal:  Blood       Date:  2008-11-20       Impact factor: 22.113
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.